BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12439609)

  • 1. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial.
    Märten A; Flieger D; Renoth S; Weineck S; Albers P; Compes M; Schöttker B; Ziske C; Engelhart S; Hanfland P; Krizek L; Faber C; von Ruecker A; Müller S; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2002 Dec; 51(11-12):637-44. PubMed ID: 12439609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
    Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
    Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
    Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
    Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
    Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
    J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
    Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
    J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.
    Rieser C; Ramoner R; Höltl L; Rogatsch H; Papesh C; Stenzl A; Bartsch G; Thurnher M
    Urol Int; 1999; 63(3):151-9. PubMed ID: 10738185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience.
    Azuma T; Horie S; Tomita K; Takahashi T; Tanaka Y; Kashiwase K; Nieda M; Takeuchi T; Ohta N; Shibata Y; Hirai H; Kitamura T
    Int J Urol; 2002 Jun; 9(6):340-6. PubMed ID: 12110099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
    Höltl L; Ramoner R; Zelle-Rieser C; Gander H; Putz T; Papesh C; Nussbaumer W; Falkensammer C; Bartsch G; Thurnher M
    Cancer Immunol Immunother; 2005 Jul; 54(7):663-70. PubMed ID: 15918076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.
    Gitlitz BJ; Belldegrun AS; Zisman A; Chao DH; Pantuck AJ; Hinkel A; Mulders P; Moldawer N; Tso CL; Figlin RA
    J Immunother; 2003; 26(5):412-9. PubMed ID: 12973030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
    Schwaab T; Schwarzer A; Wolf B; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ; Ernstoff MS
    Clin Cancer Res; 2009 Aug; 15(15):4986-92. PubMed ID: 19622576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.
    Redman BG; Chang AE; Whitfield J; Esper P; Jiang G; Braun T; Roessler B; Mulé JJ
    J Immunother; 2008; 31(6):591-8. PubMed ID: 18528294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
    J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
    Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
    J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial.
    Hernando JJ; Park TW; Kübler K; Offergeld R; Schlebusch H; Bauknecht T
    Cancer Immunol Immunother; 2002 Mar; 51(1):45-52. PubMed ID: 11845259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.
    Matsumoto A; Haraguchi K; Takahashi T; Azuma T; Kanda Y; Tomita K; Kurokawa M; Ogawa S; Takahashi K; Chiba S; Kitamura T
    Int J Urol; 2007 Apr; 14(4):277-83. PubMed ID: 17470153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
    Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
    Geiger JD; Hutchinson RJ; Hohenkirk LF; McKenna EA; Yanik GA; Levine JE; Chang AE; Braun TM; Mulé JJ
    Cancer Res; 2001 Dec; 61(23):8513-9. PubMed ID: 11731436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.